RxDoctor Payments Data

Albert Khine, MD

Gastroenterology · Portland, ORNPI 1386720274

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,002 of the $3,052 with a category attached, or 65.6%. 19 manufacturers reported payments, led by Shionogi Inc at 26.1% of the total.

$3,052in general payments, 2019–2025

Across 79 payments — averaging $38.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$795
  • Aimmune Therapeutics, Inc.$415
  • Johnson & Johnson$403
  • AbbVie$331
  • Pfizer$164
  • Nestle Healthcare Nutrition Inc.$149
  • plus $795 from 13 others

What the payments were for

  • Consulting fees$75025%
  • Food & beverage$2,00266%
  • Education$30010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,052 in reported general payments places this provider in the 85th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$33,444
Medicare patients
136
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$81,564
ZenpepLipase/Protease/Amylase20$39,195
Mesalamine29$23,264
SutabSod Sulf/Pot Chloride/Mag Sulf50$8,090
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates110$6,206
Mesalamine ErMesalamine21$4,096
Budesonide EcBudesonide11$3,417
SuprepSodium, Potassium,mag Sulfates28$2,910
Budesonide DrBudesonide21$2,906
Omeprazole45$1,080
Pantoprazole Sodium20$549
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl26$484
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$415$39,19520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →